Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Pieternella J. Lugtenburg*, Josee M. Zijlstra, Jeanette K. Doorduijn, Lara H. Bohmer, Mels Hoogendoorn, Henriette W. Berenschot, Aart Beeker, Nicole C. van der Burg-de Graauw, Harry C. Schouten, Yavuz M. Bilgin, Marie-Jose Kersten, Harry R. Koene, Alexandra H. E. Herbers, Daphne de Jong, Nathalie Hijmering, King H. Lam, Dana Chitu, Rolf E. Brouwer, Gustaaf W. van Imhoff, Dutch HOVON Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)347-355
Number of pages9
JournalBritish Journal of Haematology
Volume187
Issue number3
DOIs
Publication statusPublished - Nov 2019

Keywords

  • diffuse large B-cell lymphoma
  • relapse
  • Y-90-ibritumomab tiuxetan
  • consolidation
  • PECC
  • B-CELL LYMPHOMA
  • IBRITUMOMAB TIUXETAN
  • ELDERLY-PATIENTS
  • PLUS RITUXIMAB
  • OPEN-LABEL
  • TRIAL
  • CHOP
  • CHEMOTHERAPY
  • MULTICENTER
  • COMBINATION

Cite this